New mAb halves exacerbation rates and cuts steroid reliance in severe asthma

Dupilumab, a monoclonal antibody against the interleukin-4 receptor, has been shown to reduce exacerbations and improve lung function in moderate-severe uncontrolled asthma and also reduce reliance on steroids. The phase 3 trials, presented at ATS 2018 and published in the New England Journal of Medicine, found the benefits were seen regardless of baseline blood eosinophil ...